Foghorn Therapeutics (FHTX) Depreciation & Amortization (CF) (2019 - 2026)
Foghorn Therapeutics (FHTX) posted quarterly Depreciation & Amortization (CF) of $200000.0 for Q1 2026, down 75.82% year-over-year from $827000.0 in Q1 2025, and down 75.96% quarter-over-quarter from $832000.0 in Q4 2025.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $200000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 75.82% year-over-year to $200000.0; the TTM figure through Mar 2026 stood at $2.8 million (down 7.69% YoY), while the FY2025 annual figure was $3.3 million, up 7.48% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $200000.0, down from $832000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $900000.0 in Q3 2022, with the low at $200000.0 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $827000.0 (2022), against an average of $793294.1.
- The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) climbed 28.57% in 2025, then tumbled 75.82% in 2026.
- Foghorn Therapeutics' Depreciation & Amortization (CF) stood at $827000.0 in 2022, then increased by 8.83% to $900000.0 in 2023, then decreased by 17.67% to $741000.0 in 2024, then gained by 12.28% to $832000.0 in 2025, then sank by 75.96% to $200000.0 in 2026.
- Business Quant data shows FHTX's Depreciation & Amortization (CF) at $200000.0 in Q1 2026, $832000.0 in Q4 2025, and $900000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Foghorn Therapeutics | 347.75 Mn | 279.67 Mn | - | 200,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 200,000.00 |
| Mar 31, 2026 | 238,000.00 |
| Dec 31, 2025 | 802,000.00 |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Mar 31, 2025 | 827,000.00 |
| Dec 31, 2024 | 720,000.00 |
| Sep 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Mar 31, 2024 | 835,000.00 |
| Dec 31, 2023 | 900,000.00 |
| Sep 30, 2023 | 900,000.00 |
| Jun 30, 2023 | 800,000.00 |
| Mar 31, 2023 | 900,000.00 |
| Dec 31, 2022 | 821,000.00 |
| Sep 30, 2022 | 900,000.00 |
| Jun 30, 2022 | 800,000.00 |
| Mar 31, 2022 | 811,000.00 |
| Dec 31, 2021 | 810,000.00 |
| Sep 30, 2021 | 800,000.00 |